• Increase font size
  • Default font size
  • Decrease font size

Shares of tobacco company trading higher on FDA news

Print E-mail
By Jaime Tera   
Tuesday, 22 September 2009 09:05

Star Scientific, Inc.(NASDAQ:STSI) is a tobacco company that focuses on reducing toxins in tobacco leaf and tobacco smoke.

According to some reports, they will utilize a novel, patented method for cultivation, curing and preparation of tobacco to formulate dissolvable smokeless tobacco products. This new curing process was the subject of a patent application filed in December, 2008. Its use has resulted in tobacco leaf with significantly lower levels of tobacco-specific nitrosamines than previously achieved using the StarCured curing process

The company believes that this novel process, as reflected in its patent application, will enable the company to achieve the lowest toxin levels anywhere in the world. Star plans to submit the products to the FDA for approval to market as "modified risk" tobacco products, under Section 911 of the new Family Smoking Prevention and Tobacco Control Act, once formulation and testing of the new product is completed in early 2010.

The Company is primarily engaged in the development, implementation and licensing of its technology for the curing of tobacco to prevent the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines (TSNAs); the manufacture, sales, marketing and development of very low-TSNA dissolvable smokeless tobacco products, including ARIVA compressed powdered tobacco cigalett pieces, and STONEWALL Hard Snuff, and the licensing of trademarks for certain of its cigarette brands. Star Scientific is also engaged in the development of pharmaceutical products that have a botanical, tobacco-based component, that are designed to treat tobacco dependence and a range of neurological conditions, including Alzheimer’s disease, Parkinson’s disease, schizophrenia and depression and related products such as, neutraceuticals.





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 21 minutes ago A Stem-Cell-Based Drug Gets Approval in Canada $OSIR http://t.co/XI3gAfMY
about 1 hour ago $JNJ Zytiga, a Prostate Cancer Drug, Does Well in Trial http://t.co/v7YUm9b6
about 2 hours ago $PFE Pfizer Lung Drug Stops Deadly Child Cancers in Study | http://t.co/hcfdrnCY
about 3 hours ago Human Genome Looks to Anyone but GlaxoSmithKline | http://t.co/d4IMkIn3
about 4 hours ago When David Einhorn did not mention Herbalife $HLF as a potential short candidate, that stock shot up on Wednesday | http://t.co/XpFKihQS
about 5 hours ago Stock Market: Stocks Get Hammered On Disappointing Data, Greece Worries http://t.co/FyH8zpru
about 5 hours ago Synergy Pharmaceuticals (SGYP) May Be Ready To Roll - Small Cap Stock Market Investing Tips http://t.co/FHYXlF1Q
about 8 hours ago Alvine Presents Results from Phase 2A Trial of ALV003 in Celiac Disease Patients -2012 Digestive Diseases Week Meeting http://t.co/e6Rjhbj9

navigation

Free Phone Trade Alerts

Benzinga.com supporter Seeking Alpha Certified